Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease
NCT03737214Phase 3Completed
- Sponsor
- Idorsia
- Start
- Dec 2018
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of lucerastat in Fabry disease (FD), sponsored by Idorsia. Primary endpoint: Treatment-emergent adverse events at 10 years. Started Dec 2018; status: completed.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT03737214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737214.